By the Doktorly editorial team · Medically reviewed by the Doktorly medical team · Last updated: 14 November 2026
The practical takeaway is less dramatic than the headlines: diagnostic criteria have stayed stable, but treatment is becoming more personalised – including how co-existing conditions, sleep and lifestyle are factored in. We keep this page updated as new peer-reviewed findings land.
ADHD is increasingly viewed in the context of neurodiversity. This means differences in attention, stimulus processing and self-regulation are understood not only as a deficit but also as neurological variation – while there is a real need for treatment when suffering exists.
Research on ADHD has moved: from "a childhood disorder you outgrow" to a lifelong neurodevelopmental profile with real brain-level correlates. This page summarises what has actually changed – and what it means for treatment in practice.
The perspective can reduce stigma and strengthen resources. At the same time, it must not trivialise medical needs. What matters is individualised care instead of black-and-white thinking.
No. Treatment makes sense when there is suffering. Neurodiversity and therapy are not mutually exclusive.
No. Research refines care but does not replace clinically effective building blocks.
A large one. Good psychoeducation improves understanding, adherence and long-term treatment success.
Conclusion: Modern ADHD care in 2026 combines evidence-based treatment with a respectful, neurodiversity-oriented attitude.